Login
$IRD
$4.10 +$0.06 (1.49%) After hours

Company Executives

Officer Age In this role 2025 pay Source
George Magrath Also a director
Chief Executive Officer
42 Not stated $1,493,383
Robert Gagnon
Chief Financial Officer
51 Since 2025
1 year
Not reported
Benjamin R. Yerxa Also a director
President
60 Not stated Not reported
Joseph Schachle
Chief Operating Officer
61 Since 2023
3 years
$718,408
Ashwath Jayagopal
Chief Scientific & Dev. Ofc.
Title from the Form 4 dated Apr 23, 2026
44 Not stated $764,848
Amy Rabourn
Head of Fin. Quality Assurance
Title from the Form 4 dated Apr 23, 2026
46 Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
9
serving now
Independent
6 of 6
stated in the proxy; 3 not stated
Average tenure
4.3 years
from year joined
CEO also chairs the board
No
Cam Gallagher
Director Age On board Independent Committees Other public boards 2025 pay Source
Cam Gallagher
56 2020
6 years
Independent
Compensation · Chair
None stated $295,967
Dr. George Magrath
42 2023
3 years
Not stated None stated None stated Paid as CEO
Sean Ainsworth
58 2020
6 years
Independent
Audit
None stated $210,137
Dr. Benjamin R. Yerxa
60 2024
2 years
Not stated None stated Clearside Biomedical, Inc. Not stated
Dr. Jean Bennett
71 2024
2 years
Not stated None stated REGENXBIO, Inc. $168,503
Susan K. Benton
61 2020
6 years
Independent
Compensation
None stated $180,137
Dr. Adrienne Graves
72 2024
2 years
Independent
Nominating and Corporate Governance
Ocular Therapeutix, Inc., Harrow, Inc. $171,443
Dr. James S. Manuso
77 2020
6 years
Independent
Nominating and Corporate Governance · Chair
TuHura Biosciences, Inc. $188,917
Richard Rodgers
59 2020
6 years
Independent
Audit · Chair
Ardelyx, Inc., Novavax, Inc. $189,450

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

8 disclosed in the proxy filed Mar 23, 2026
Dr. Pepose
former director of the Company
$0.5 million
fiscal year 2025

Consulting agreement under which Dr. Pepose was paid a monthly consulting fee and received 32,000 RSUs and options to purchase 48,000 shares; the Company incurred related consulting expenses in fiscal year 2025

Amount not stated
March 21, 2025

Subscription agreement to purchase 392,157 shares of Common Stock and receive 392,157 warrants in a private offering

Amount not stated
March 21, 2025

Subscription agreement to purchase 784,314 shares of Common Stock and receive 784,314 warrants in a private offering

Cam Gallagher
Chair of the Company’s Board
$1.0 million

Investment of $1.0 million in the August 2025 Private Placement

Sean Ainsworth
the lead independent director of the Board
$0.1 million

Participation in the August 2025 Private Placement with an investment of $0.1 million

Foundation Fighting Blindness
significant stockholder of the Company
A total of $2.0 million
2022

2022 binding letter agreement to collaborate on natural history studies, requiring the Company to provide a total of $2.0 million of funding, superseded in 2025

With Jaeb Center for Health Research Open in proxy
Foundation Fighting Blindness
significant stockholder of the Company
$0.3 million
fiscal year 2025

2025 letter agreement to collaborate on a study of retinal dystrophies; the Company paid $0.3 million in fiscal year 2025 and must fund one more installment of $0.3 million

With Jaeb Center for Health Research Open in proxy
Retinal Degeneration Fund
sole member is Foundation Fighting Blindness
Up to $2.0 million
June 2025

Funding agreement providing nondilutive funding of up to $2.0 million for the MERTK Program, with $1.0 million disbursed in June 2025, and royalty and milestone payment obligations to RDF

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support